| pubmed-article:19633472 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0441769 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:19633472 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19633472 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19633472 | pubmed:dateCreated | 2009-7-27 | lld:pubmed |
| pubmed-article:19633472 | pubmed:abstractText | This phase II study assessed the clinical activity of neoadjuvant therapy with carboplatin, gemcitabine, and thalidomide in patients with stage IIB to IIIA non-small cell lung cancer (NSCLC). A secondary goal was to assay a panel of candidate serum biomarkers before and after neoadjuvant therapy. | lld:pubmed |
| pubmed-article:19633472 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19633472 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19633472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19633472 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19633472 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19633472 | pubmed:issn | 1556-1380 | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:KratzkeRobert... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:MaddausMichae... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:LarsonTimothy... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:GuptaVinitaV | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:DudekArkadius... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:DragnevKonsta... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:Lesniewski-Km... | lld:pubmed |
| pubmed-article:19633472 | pubmed:author | pubmed-author:IsakssonRache... | lld:pubmed |
| pubmed-article:19633472 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19633472 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:19633472 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19633472 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19633472 | pubmed:pagination | 969-75 | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:meshHeading | pubmed-meshheading:19633472... | lld:pubmed |
| pubmed-article:19633472 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19633472 | pubmed:articleTitle | Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. | lld:pubmed |
| pubmed-article:19633472 | pubmed:affiliation | Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA. dudek002@umn.edu | lld:pubmed |
| pubmed-article:19633472 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19633472 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19633472 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19633472 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
